Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and lead radioisotopes

gemcitabine has been researched along with lead radioisotopes in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abdulla, A; Albert, PS; Brady, ED; Brechbiel, MW; Flynn, J; Garmestani, K; Milenic, DE1
Baidoo, KE; Brechbiel, MW; Milenic, DE; Yong, KJ2

Other Studies

3 other study(ies) available for gemcitabine and lead radioisotopes

ArticleYear
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lead Radioisotopes; Linear Energy Transfer; Mice; Mice, Nude; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2007
Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    International journal of radiation oncology, biology, physics, 2013, Mar-15, Volume: 85, Issue:4

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Chromatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Repair; Drug Synergism; Female; G2 Phase; Gemcitabine; Heterocyclic Compounds; Humans; In Situ Nick-End Labeling; Isothiocyanates; Lead Radioisotopes; Linear Energy Transfer; Mice; Mice, Nude; Mitosis; Peritoneal Neoplasms; Phosphorylation; Protein Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays

2013
Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lead Radioisotopes; Mice; Trastuzumab

2016